You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

346 Results
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Guidelines and Advice
Status: In-Review
ID: 7-13
Oct 2017
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
irinotecan,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Drug
Other Name(s): Gleevec®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Document
New
Jan 2025
Drug
Other Name(s): Camptosar®
Quick Link(s): Drug Monograph, Patient Info Sheet
Apr 2023
Symptom Management
Symptom Management
Drug
Other Name(s): Sarclisa®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2024
Drug
Other Name(s): Inrebic®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025

Pages